Status:
COMPLETED
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
Lead Sponsor:
Centocor, Inc.
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.
Detailed Description
CNTO 888 is an antibody that works by blocking a protein called CC-chemokine ligand 2 (CCL2). In research studies CCL2, has been shown to increase the growth of new blood vessels which help the tumor ...
Eligibility Criteria
Inclusion
- Documentation of an advanced solid tumor
- No more than 2 previous anticancer therapies
- good performance status
- adequate bone marrow, liver, and renal function / adequate blood test values
- willing to use birth control measures
Exclusion
- No residual toxicities resulting from previous therapy
- no known allergies, hypersensitivity, or intolerance to antibodies or chemotherapies
- clinically significant bleeding or requiring concurrent therapeutic dose of anticoagulation
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT01204996
Start Date
May 1 2010
End Date
November 1 2011
Last Update
May 30 2012
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Detroit, Michigan, United States
2
Tacoma, Washington, United States
3
Barcelona, Spain
4
Madrid, Spain